A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

NCT04868760 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: Ipilimumab
DRUG: IBI310

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.